tbuckley/cabot-search huggingface dataset:
Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study
Authors: Robert M. Rifkin, Jason M. Melear, Edward Faber, William I. Bensinger, John M Burke, Mohit Narang, Don Stevens, Sriya Gunawardena, Yana Lutska, Keqin Qi, Jon Ukropec, Ming Qi, Thomas S. Lin, Habte A Yimer
Journal: Blood (2019)
KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)
Authors: Madan Jagasia, Amandeep Salhotra, Carlos R. Bachier, Behyar Zoghi, MD, PhD, FACP, Aleksandr Lazaryan, Daniel J. Weisdorf, James Essell, Laurie S. Green, Olivier Schueller, Lindy Huang, Zhongming Yang, David Eiznhamer, Sanjay K. Aggarwal, Bruce R. Blazar, Stephanie J. Lee
Journal: Blood (2019)
A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia
Authors: Junfang Yang, Jiaping He, Xian Zhang, Zhenguang Wang, Yongliang Zhang, Songbai Cai, Zhe Sun, Xun Ye, Yan He, Lianjun Shen, Jiujiang He, Gailing Zhang, Dan Song, Min Zhang, Xiaona Hu, Jingjing Li, Shulian Xia, Li Xu, Wei Cao, Peihua Lu
Journal: Blood (2019)
Mutations Beget More Mutations—Rapid Evolution of Mutation Rate in Response to the Risk of Runaway Accumulation
Authors: Yongsen Ruan, Haiyu Wang, Bingjie Chen, Haijun Wen, Chung-I Wu
Journal: Molecular Biology and Evolution (2019)

Abstract The rapidity with which the mutation rate evolves could greatly impact evolutionary patterns. Nevertheless, most studies simply assume a constant rate in the time scale of interest (Kimura 1983; Drake 1991; Kumar 2005; Li 2007; Lynch 2010). In contrast, recent studies of somatic mutations suggest that the mutation rate may vary by several orders of magnitude within a lifetime (Kandoth et al. 2013; Lawrence et al. 2013). To resolve the discrepancy, we now propose a runaway model, applicable to both the germline and soma, whereby mutator mutations form a positive-feedback loop. In this loop, any mutator mutation would increase the rate of acquiring the next mutator, thus triggering a runaway escalation in mutation rate. The process can be initiated more readily if there are many weak mutators than a few strong ones. Interestingly, even a small increase in the mutation rate at birth could trigger the runaway process, resulting in unfit progeny. In slowly reproducing species, the need to minimize the risk of this uncontrolled accumulation would thus favor setting the mutation rate low. In comparison, species that starts and ends reproduction sooner do not face the risk and may set the baseline mutation rate higher. The mutation rate would evolve in response to the risk of runaway mutation, in particular, when the generation time changes. A rapidly evolving mutation rate may shed new lights on many evolutionary phenomena (Elango et al. 2006; Thomas et al. 2010, 2018; Langergraber et al. 2012; Besenbacher et al. 2019).
The development and implementation of a gynecologic cancer survivorship tool.
Authors: Jeanne Carter, Nadeem Abu-Rustum, Sally Saban, Ling Y. Chen, Andrew Vickers, Gabriela Billanti, Nicole A Connors, Vance Broach, Carol L. Brown, Dennis Chi, Ginger J. Gardner, Deborah J. Goldfrank, Elizabeth Lin Jewell, Mario M. Leitao, Kara C. Long-Roche, Jennifer Jean Mueller, Yukio Sonoda, Oliver Zivanovic
Journal: Journal of Clinical Oncology (2019)

98 Background: To assess the implementation and use of an electronic survivorship tool to enhance patient/clinician communication and intervention of survivorship concerns in women treated for gynecologic cancer. Methods: The clinical survivorship tool was developed using evidence-based data, multidisciplinary expert input, and patient feedback. The tool is composed of 17 questions encompassing 6 main categories: gynecologic health (abnormal bleeding/pain), lymphedema, vaginal/vulvar dryness, sexual health concerns, menopause (hot flushes, sleep difficulties), and bowel/urinary issues. The electronic tool was piloted and incorporated into clinic for endometrial and cervical cancer patients. Patients were introduced to the tool at their first postop visit and emailed an introduction form before their 3-month follow-up visit. The form could be completed at home or at the time of scheduled visit. Results: From 6/1/18 to 6/1/19, 1269 patients were eligible to complete at least one survivorship tool survey. Compliance rates increased over the year and reached 67% (1,015/1,525 assigned surveys completed) with the addition of clinic coordinator, staff and nurse training; the initiation of daily emails screening for survey respondents; clinic coordinator feedback and modification of screening emails; and the addition of nurses to daily screening emails. Of those who completed surveys between 01/1/19 and 06/1/19, the most common survivorship concerns noted were bowel (48%, n=484) and urinary function (35%,n=352) issues, menopausal symptoms such as trouble sleeping (33%, n=333) and hot flashes (25%, n=249), lower extremity symptoms (heaviness 17%, n=175; swelling 17%, n=171; numbness 17%, n=171), and vaginal dryness (26%, n=263), with actionable items of education and referrals, as needed. Conclusions: This survivorship tool enhanced the ability of healthcare providers to identify, monitor, and address survivorship concerns over the continuum of care. Patients and healthcare providers found this tool to be clinically feasible with potential to promote communication and education to enhance clinical care. Our multidisciplinary approach and training were key to implementation success.
Abstract 32: Chest Compression Fraction Increased When Police Used AED That Analyses Heart Rhythm During CPR
Authors: Corina de Graaf, Stefanie G Beesems, Ronald E Stickney, Fred W Chapman, Rudolph W Koster
Journal: Circulation (2019)

Introduction: Conventional automated external defibrillators (AED) prompt rescuers to stop cardiopulmonary resuscitation (CPR) for ECG analysis during cardiac arrest (CA), but pauses in CPR are associated with worse outcome. A new AED algorithm, cprINSIGHT™ Analysis Technology, analyses the ECG while rescuers continue chest compressions. Hypothesis: Compared to conventional AEDs, AEDs with the cprINSIGHT algorithm will lead to fewer and shorter interruptions of chest compressions for ECG analysis and, thereby, a higher chest compression fraction (CCF). Methods: Amsterdam Police used conventional AEDs in 2016 (LIFEPAK® 1000 defibrillator) and AEDs with cprINSIGHT in 2018 (LIFEPAK CR2 AED); in the CR2 AED, cprINSIGHT is activated after the first conventional analysis. We analysed AED data from control CA cases in 2016 and intervention CA cases in 2018, comparing pre-shock pause, median CCF and CCF categories. CCF was defined as the proportion of time with chest compressions in the period from the start of CPR after analysis 1 to the start of CPR after analysis 2. The CCF analysis included only cases where CPR was provided with a ratio of 30 compressions to 2 ventilations. Results: Data from 111 control and 87 intervention cases were analysed. The initial recorded rhythm was shockable in 42 control cases (38%) and 36 intervention cases (41%). Rhythm during analysis 2 was shockable in 28/103 (27%) control and 19/80 (24%) intervention cases; 15 cases had no second analysis. In 67/80 (84%) intervention cases, analysis 2 reached a decision without prompting for a CPR pause. Intervention cases had a significantly shorter pre-shock pause than control cases (7 sec vs 22 sec, p &lt; 0.001) and significantly higher median CCF (87% vs 77%, P&lt;0.001). CCF was ≥90% in 38% of intervention cases and 10% of control cases (figure). Conclusion: The use of the cprINSIGHT algorithm in AEDs leads to a shorter pre-shock pause, fewer analysis pauses and an increase in CCF compared to conventional AEDs.
Correction to: KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer
Authors: Yingying Qian, Shoujie Chai, Zuyu Liang, Yongfang Wang, You Zhou, Xia Xu, Chenchen Zhang, Min Zhang, Jingxing Si, Feiteng Huang, Zhangdan Huang, Wei Hong, Kai Wang
Journal: Molecular Cancer (2019)

After the publication of this work [1],
The Premodern Sensibility of Elisabeth Kübler-Ross in a Metamodern Age: What <i>On Death and Dying</i> Means Now
Authors: Anthony L Back
Journal: The American Journal of Bioethics (2019)

I first read On Death and Dying almost 40 years ago as a college senior, when I was still struggling to adjust to my mother’s death from preleukemia. The book was already a classic. Kubler-Ross’s v...
Episodic Visual Snow Associated With Migraine Attacks
Authors: Julius Hodak, Urs Fischer, Claudio L. A. Bassetti, Christoph J. Schankin
Journal: JAMA Neurology (2019)

Visual snow syndrome (VSS) is a debilitating disorder characterized by continuous visual snow (VS), ie, tiny flickering dots in the entire visual field resembling the view of a badly tuned analog television (Figure), plus additional visual symptoms, such as photophobia and palinopsia.There is a high comorbidity with migraine and migraine aura. 1 To our knowledge, this is the first report of patients with an episodic form of VS (eVS), strictly co-occurring with migraine attacks.Methods | Between January 2016 and December 2017, we saw 3 patients with eVS and 1934 patients with migraine at our tertiary outpatient headache center.Diagnoses were made according to the International Headache Society International Classification of Headache Disorders-3 2 and our previous work, 1 except for the requirement of permanence for VS.
A novel risk-based approach simulating oncologic surveillance according to smoking status after radical nephroureterectomy with upper tract urothelial carcinoma
Authors: K. Shigeta, E. Kikuchi, T. Abe, M. Hagiwara, K. Ogihara, N. Tanaka, T. Takeda, K. Matsumoto, R. Mizuno, M. Oya
Journal: Annals of Oncology (2019)
Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial
Authors: Arnon P Kater, Jenny Qun Wu, Julie Dubois, Christopher R Bolen, Zoe J Assaf, Peter Hillmen, Barbara F. Eichhorst, Eric F Eldering, Thomas J. Kipps, Anton W Langerak, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Carolyn Owen, Brenda J Chyla, Elizabeth A Punnoose, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, Yanwen Jiang, John F. Seymour
Journal: Blood (2019)
Management of severe acute pancreatitis
Authors: O Joe Hines, Stephen J Pandol
Journal: BMJ (2019)

ABSTRACT The risks, measurements of severity, and management of severe acute pancreatitis and its complications have evolved rapidly over the past decade. Evidence suggests that initial goal directed therapy, nutritional support, and vigilance for pancreatic complications are best practice. Patients can develop pancreatic fluid collections including acute pancreatic fluid collections, pancreatic pseudocysts, acute necrotic collections, and walled-off necrosis. Several randomized controlled trials and cohort studies have recently highlighted the advantage of managing these conditions with a progressive approach, with initial draining for infection followed by less invasive techniques. Surgery is no longer an early intervention and may not be needed. Instead, interventional radiologic and endoscopic methods seem to be safer with at least as good survival outcomes. Newly developed evidence based quality indicators are available to assess and improve performance. Development and clinical testing of drugs to target the mechanisms of disease are necessary for further advancements.
Going Beyond Results of the PEMBRO-RT Trial—Reply
Authors: Willemijn S. M. E. Theelen, Paul Baas
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Piloting workshops to enhance hope among patients with advanced breast cancer and oncologists.
Authors: Mirat Shah, Anna K. Ferguson, Orit Gutfeld, Dvora Corn, Ravi Varadhan, Vered Stearns, B. Douglas Smith, Thomas J. Smith, Benjamin W. Corn
Journal: Journal of Clinical Oncology (2019)

137 Background: Hope is a modifiable entity that can be separated from cancer outcome. Increasing hopefulness in patients with advanced breast cancer and oncologists may be of intrinsic value. The feasibility and efficacy of a short intervention to increase hopefulness in these groups are unknown. Methods: We enrolled eligible participants at 2 medical centers into 2 cohorts- 1 for patients with advanced breast cancer and 1 for oncologists. The intervention, a half-day hope enhancement workshop (HEW), was conducted in groups of 10-15 participants within each cohort. Participants completed evaluations including the Adult Hope Scale (AHS) and Herth Hope Index (HHI) pre-workshop, post-workshop, and at 3 months. Mean scores were compared across time points within each cohort using paired t-tests. Results: Ten out of 13 consented patients (76.9%) and all 26 consented physicians (100%) participated in the HEW, meeting our feasibility threshold. In patients, the mean AHS score increased significantly from 50.60 (SD 4.88) pre-workshop to 56.50 (SD 4.74) post-workshop (t = 3.99, p = 0.003); the mean HHI score also increased but this trend was not significant. In oncologists, the increases in mean AHS and HHI scores post-workshop were smaller and not significant. A summary is shown in the table. Post-workshop, patients and physicians were inclined to apply what they learned. However, at 3 months, less than half of participants responded to the evaluation. Mean AHS and HHI scores in patients fell back to baseline values. Conclusions: A short intervention to enhance hope was feasible and associated with increased hopefulness in patients, which was not maintained. Next steps for patients include “maintenance hope therapy” with earlier follow-up and more sustained contact post-workshop. Among oncologists, we hypothesize that for those not grappling with poor prognoses, reframing hope may be less effective, and they may feel less urgency to augment their hopefulness. [Table: see text]
Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines
Authors: Holger J. Schünemann, Donata Lerda, Cecily Quinn, Markus Follmann, Pablo Alonso-Coello, Paolo Giorgi Rossi, Annette Lebeau, Lennarth Nyström, Mireille Broeders, Lydia Ioannidou-Mouzaka, Stephen W. Duffy, Bettina Borisch, Patricia Fitzpatrick, Solveig Hofvind, Xavier Castells, Livia Giordano, Carlos Canelo-Aybar, Sue Warman, Robert Mansel, Francesco Sardanelli, Elena Parmelli, Axel Gräwingholt, Zuleika Saz-Parkinson
Journal: Annals of Internal Medicine (2019)

Description: The European Commission Initiative for Breast Cancer Screening and Diagnosis guidelines (European Breast Guidelines) are coordinated by the European Commission's Joint Research Centre. The target audience for the guidelines includes women, health professionals, and policymakers. Methods: An international guideline panel of 28 multidisciplinary members, including patients, developed questions and corresponding recommendations that were informed by systematic reviews of the evidence conducted between March 2016 and December 2018. GRADE (Grading of Recommendations Assessment, Development and Evaluation) Evidence to Decision frameworks were used to structure the process and minimize the influence of competing interests by enhancing transparency. Questions and recommendations, expressed as strong or conditional, focused on outcomes that matter to women and provided a rating of the certainty of evidence. Recommendations: This synopsis of the European Breast Guidelines provides recommendations regarding organized screening programs for women aged 40 to 75 years who are at average risk. The recommendations address digital mammography screening and the addition of hand-held ultrasonography, automated breast ultrasonography, or magnetic resonance imaging compared with mammography alone. The recommendations also discuss the frequency of screening and inform decision making for women at average risk who are recalled for suspicious lesions or who have high breast density.
Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study
Authors: C. Huang, Y. Yang, A. Kwong, S.-C. Chen, L.-M. Tseng, M.-C. Liu, K. Shen, S. Wang, T.-Y. Ng, Y. Feng, G. Sun, I.R. Yan, Z. Shao
Journal: Annals of Oncology (2019)
Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis
Authors: Shari Rogal, Ada Youk, Hongwei Zhang, Walid F. Gellad, Michael J. Fine, Chester B. Good, Maggie Chartier, Andrea DiMartini, Timothy Morgan, Ramon Bataller, Kevin L. Kraemer
Journal: Hepatology (2019)

Despite the significant medical and economic consequences of coexisting alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns and their impact on clinical outcomes in this population. We aimed to characterize the use of and outcomes associated with AUD treatment in patients with cirrhosis.This retrospective cohort study included Veterans with cirrhosis who received Veterans Health Administration care and had an index diagnosis of AUD between 2011 and 2015. We assessed the baseline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outcomes for 180 days following the first AUD diagnosis code within the study time frame. Among 93,612 Veterans with cirrhosis, we identified 35,682 with AUD, after excluding 2,671 who had prior diagnoses of AUD and recent treatment. Over 180 days following the index diagnosis of AUD, 5,088 (14%) received AUD treatment, including 4,461 (12%) who received behavioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both behavioral therapy and pharmacotherapy. In adjusted analyses, behavioral and/or pharmacotherapy-based AUD treatment was associated with a significant reduction in incident hepatic decompensation (6.5% vs. 11.6%, adjusted odds ratio [AOR], 0.63; 95% confidence interval [CI], 0.52, 0.76), a nonsignificant decrease in short-term all-cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0.57, 1.08), and a significant decrease in long-term all-cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.80, 0.96).Most Veterans with cirrhosis and coexisting AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6-month follow-up. The reductions in hepatic decompensation and mortality suggest that future studies should focus on delivering evidence-based AUD treatments to patients with coexisting AUD and cirrhosis.
Cancer and therapy in the 16th century: the unique case of adenocarcinoma in Luigi Carafa, prince of Stigliano (1511–76)
Authors: Antonio Fornaciari, Raffaele Gaeta, Silvio Chericoni, Fabio Stefanelli, Antonio Giuseppe Naccarato, Maura Castagna, Riccardo Lencioni, Valentina Giuffra, Gino Fornaciari
Journal: The Lancet Oncology (2019)
MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling
Authors: Srividya Swaminathan, Line Dam Heftdal, Daniel Liefwalker, Renumathy Dhanasekaran, Anja Deutzmann, Crista Horton, Adriane Mosley, Mariola Liebersbach, Andrew Gentles, Holden T. Maecker, Dean Felsher
Journal: Blood (2019)
Digital Supportive Care Awareness and Navigation (D-SCAN): Results of a pilot randomized trial.
Authors: Thomas William LeBlanc, Cheyenne Corbett, Debra M. Davis, Kris Herring, Susan C. Locke, Jesse D Troy, Steven Wolf, Yousuf Zafar, Darren Atlee, Jack Chilcott, Hugo Manassei, Colette McCoy, Sean Mohan, Trudy Pendergraft, Steven R. Patierno
Journal: Journal of Clinical Oncology (2019)

101 Background: Cancer patients face many supportive care needs. In crowded clinics with rising care complexity, clinicians struggle to assess and manage these needs. Duke Cancer Patient Support Program (DCPSP) services aim to bridge this gap, but many patients are unaware of these services. We hypothesized that a DCPSP mobile application (app) is a feasible approach to this problem. Methods: We developed an app to enhance DCPSP awareness and facilitate weekly symptom reporting (via the Edmonton Symptom Assessment Scale, ESAS). Based upon symptoms, the app presents information cards and recommendations for specific DCPSP services. We enrolled 50 patients with advanced cancer (2 arms; 25 app intervention, 25 control) and 10 caregivers to a 12-week pilot trial. The primary outcome was feasibility. Secondary measures assessed knowledge/engagement of DCPSP services, usability, satisfaction, quality of life (QoL), and activation. We interviewed a subset of participants about the experience. Results: Forty-five patients completed the study, exceeding our pre-determined feasibility threshold. Most patients were age 50-64; the most common cancers were breast (42%) and lung (18%). Knowledge/use of DCPSP services increased in both arms, with a larger trend in the intervention arm (2.5 vs 4.0 composite score increase). App patients (n=25) completed a median of 7 ESAS surveys for an overall response rate of 57%. The most commonly-reported moderate/severe symptoms were fatigue (40%), drowsiness (22%), and pain (20%), with 54% of surveys from 23 of 25 patients reporting at least one moderate/severe symptom. These patients averaged 20 app interactions versus 9 interactions for those without a moderate/severe symptom. Satisfaction scores were high, and qualitative feedback was positive. We found no differences in QoL or patient activation across study arms. Caregivers had significant improvement in awareness/use of services (median increase 4.5, p=0.01). Conclusions: The D-SCAN app is a feasible approach to augmenting supportive care awareness and navigation, with high satisfaction and usability scores. The trend towards enhanced awareness and engagement of DCPSP services in app utilizers warrants further testing. Clinical trial information: NCT03628794.